MedicalCV Announces Sales of the Omnicarbon(R) Mechanical Heart Valve to Cease on April 30, 2005

MedicalCV Announces Sales of the Omnicarbon(R) Mechanical Heart
Valve to Cease on April 30, 2005
Company Gaining Market Recognition of Its ATRILAZE(TM) Surgical Ablation System



MINNEAPOLIS, April 8  /PRNewswire-FirstCall/ -- MedicalCV, Inc. (OTC:MDCV)
(BULLETIN BOARD: MDCV) , http://www.medcvinc.com/ , a cardiovascular surgery
device manufacturer, focusing on the surgical needs surrounding atrial
fibrillation, announced today that it will discontinue distribution of its
Omnicarbon(R) mechanical heart valve product line at the end of this fiscal
year.

"Since November 2004, management and the board of directors have been
evaluating and seeking strategic alternatives for the Omnicarbon(R) mechanical
heart valve product line.  We previously announced that we were discontinuing
the manufacture of valves.  We have now determined to exit the heart valve
segment entirely.  We were unable to generate a viable opportunity to dispose
of this product line and it had become a continuing diversion of management and
board time, which is better directed toward completing the repositioning of our
company.  The Company will focus on building industry support and acceptance
for its ATRILAZE(TM) Surgical Ablation System.

"We are very excited about our AtriLaze(TM) technology and the significant
market opportunity it offers for the treatment of atrial fibrillation that we
must commit all of our resources to the AtriLaze(TM) system," said Marc P.
Flores, President and CEO of MedicalCV, Inc.

Flores continued, "The recently announced closing of private financing provides
us the capital resources to continue development of a stand-alone, minimally
invasive (closed-chest, beating heart) surgical procedure for the treatment of
atrial fibrillation.  The AtriLaze(TM) system is already gaining industry
traction and recognition, as it received an excellence in technology award for
its technology from Frost & Sullivan, a leading industry market research firm,"
concluded Flores.

About MedicalCV, Inc.

MedicalCV, Inc., a cardiovascular surgery device manufacturer, focuses on the
design, development and commercialization of new, improved and enhanced
technologies, products, methods and techniques to treat cardiovascular
disorders and disease, including products targeting the treatment of atrial
fibrillation ("AF").  Historically, MedicalCV developed and marketed
Omnicarbon(R) mechanical heart valves utilizing its proprietary pyrolytic
carbon processes.  Although the Company ceased manufacturing new heart valves
in September 2004, it had continued to maintain the mechanical heart valve
business, supporting customers and distributors during the divestiture process.
 After April 30, 2005, the Company will discontinue sales of the Omnicarbon(R)
heart valve.  The Company is concentrating its resources on the AF market.  The
Company's core technology is the ATRILAZE(TM) Surgical Ablation System, for use
in cardiac tissue ablation in surgery, which the Company acquired on August 27,
2003 and for which it received FDA 510(k) clearance on November 30, 2004.  The
Company's common stock is traded on the OTC Bulletin Board under the symbol
"MDCV".

For further information on MedicalCV, Inc., please visit
http://www.medcvinc.com/ .

You may register to receive MedicalCV's future press releases and to be added
to the Company's distribution list by visiting: http://www.roiny.com/form.php .

This release contains certain forward-looking statements of expected future
developments, as defined in the Private Securities Litigation Reform Act of
1995.  The forward-looking statements in this release refer to our expectations
regarding disposition of our heart valve business, operating improvements,
development of atrial fibrillation product and minimally invasive treatment of
atrial fibrillation.  These forward-looking statements reflect management's
expectations and are based on currently available data; however, actual results
are subject to future risks and uncertainties, which could materially affect
actual performance.  Risks and uncertainties that could affect such performance
include, but are not limited to, the following: the Company's ability to fund
significant capital needs; market acceptance in the U.S. of the Company's
cardiovascular products; acceptance of minimally invasive techniques for the
reduction of atrial fibrillation through ablation; potential reductions in
pricing by competitors; the costs of licensing and acquiring new products and
technologies; the time and costs involved in obtaining regulatory clearance for
cardiovascular products; competing technological and market developments;
physician acceptance of the Company's cardiovascular products; dependence upon
governmental reimbursements and third party supplies; and the strength of the
market for cardiovascular products. For more detailed information about these
risks and uncertainties, please review the Company's Annual Report on Form
10-KSB for the fiscal year ended April 30, 2004 and our 8-K report filed with
the Securities and Exchange Commission on January 6, 2005.

These events and uncertainties are difficult or impossible to predict
accurately and many are beyond the Company's control.  The Company assumes no
obligation to publicly release the results of any revisions that may be made to
any forward-looking statements to reflect events or uncertainties after the
date of such statements or to reflect the occurrence of anticipated or
unanticipated events.

   MedicalCV, Inc. Contact:         Investor Relations Contact:
   Marc P. Flores                   ROI Group Associates, Inc.
   President and CEO                Robert Giordano / Sarah Shepard
   Phone [phone]               President / Vice President
                Phone [phone], ext. 10 / 17
   http://www.medcvinc.com/           / 
                                    http://www.roiny.com/

DATASOURCE: MedicalCV, Inc.



CONTACT:  Marc P. Flores, President and CEO of MedicalCV, Inc.,

[phone], or  ; or investor relations, Robert

Giordano, President, ext. 10, or  , or Sarah Shepard, Vice

President, ext. 17, or  , both of ROI Group Associates,

Inc., [phone], for MedicalCV, Inc.



Web site:  http://www.roiny.com/ 

Web site:  http://www.medcvinc.com/

http://www.roiny.com/form.php 

Copyright